MENU
The COLCARDIO-ACS study site initiation visit was led by Prof. Sanjay Patel from the University of Sydney for the National Hospital of Sri Lanka with Dr Gamini Galappaththi and Dr. Anidu Pathirana with the study team from RemediumOne.
The participating study sites across Sri Lanka are:
National Hospital of Sri Lanka, Colombo 10
CLINMARC, National Hospital of Sri Lanka, Colombo 10
Kandy National Hospital
Colombo North Teaching Hospital, Ragama
Negombo District General Hospital
Colombo South Teaching Hospital, Kalubowila
Teaching Hospital Polonnaruwa
General Sir John Kotelawala Defence University Hospital, Boralesgamuwa
Jaffna Teaching Hospital
Kurunegala Teaching Hospital
Led by Professor Anthony Keech and Associate Professor Sanjay Patel from the NHMRC Clinical Trials Centre, University of Sydney, the COLCARDIO-ACS study is set to explore a promising approach to secondary prevention in heart disease.
This multicenter randomized trial will investigate whether adding low-dose colchicine to standard post-ACS treatment can reduce recurrent cardiac events in high-risk patients. By targeting atherosclerosis-associated inflammation, the study aims to improve long-term outcomes for heart attack survivors.
These patients have the highest risk of another cardiac event and are expected to benefit most from colchicine. They will be assigned to receive either 0.5 mg of oral colchicine or a matched placebo daily for three years. All participants will be followed regularly for an average of three years, and data on cardiac events will be collected. The results of this trial will add to the evidence on treatments for this high‑risk group, complementing ongoing studies, and could provide a low‑cost, effective option for those who need it most.
